Lexicon Pharmaceuticals | LXRX - Selling And Administration Expenses


Lexicon Pharmaceuticals reported $3.98M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 3.27B 138M Mar/2026
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Coherus Biosciences USD 15M 6.26M Dec/2025
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Illumina USD 272M 11M Mar/2026
Insmed USD 247.26M 34.78M Mar/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.03B 719M Mar/2026
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
MacroGenics USD 9.71M 1.77M Mar/2026
MannKind USD 54.08M 4.33M Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Novartis USD 3.14B 296M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Thermo Fisher Scientific USD 1.8B 179M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024